JP4511090B2 - Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 - Google Patents

Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 Download PDF

Info

Publication number
JP4511090B2
JP4511090B2 JP2001321828A JP2001321828A JP4511090B2 JP 4511090 B2 JP4511090 B2 JP 4511090B2 JP 2001321828 A JP2001321828 A JP 2001321828A JP 2001321828 A JP2001321828 A JP 2001321828A JP 4511090 B2 JP4511090 B2 JP 4511090B2
Authority
JP
Japan
Prior art keywords
pseudovirus
cells
plasmid
mice
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001321828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003024058A (ja
Inventor
リアン，クィアオ
ウェイ，シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2003024058A publication Critical patent/JP2003024058A/ja
Application granted granted Critical
Publication of JP4511090B2 publication Critical patent/JP4511090B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001321828A 2001-05-15 2001-10-19 Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 Expired - Fee Related JP4511090B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN01118003A CN1114690C (zh) 2001-05-15 2001-05-15 乳头瘤假病毒及其制备方法
CN01118003.X 2001-05-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007124042A Division JP4472724B2 (ja) 2001-05-15 2007-05-09 パピロマウイルス偽ウイルス及びその調製方法

Publications (2)

Publication Number Publication Date
JP2003024058A JP2003024058A (ja) 2003-01-28
JP4511090B2 true JP4511090B2 (ja) 2010-07-28

Family

ID=4662911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001321828A Expired - Fee Related JP4511090B2 (ja) 2001-05-15 2001-10-19 Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法
JP2007124042A Expired - Fee Related JP4472724B2 (ja) 2001-05-15 2007-05-09 パピロマウイルス偽ウイルス及びその調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007124042A Expired - Fee Related JP4472724B2 (ja) 2001-05-15 2007-05-09 パピロマウイルス偽ウイルス及びその調製方法

Country Status (4)

Country Link
US (3) US6878541B2 (enExample)
JP (2) JP4511090B2 (enExample)
CN (1) CN1114690C (enExample)
WO (1) WO2002092796A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114690C (zh) 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20120164173A1 (en) * 2001-05-15 2012-06-28 Liang Qiao Papilloma Pseudovirus and Preparation
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2686990C (en) 2007-05-08 2018-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus pseudoviruses for detection and therapy of tumors
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
WO2011053675A2 (en) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN104334196B (zh) 2012-02-16 2018-04-10 Atyr 医药公司 用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
EP3517130B1 (en) 2013-09-18 2022-03-30 Aura Biosciences, Inc. Method of producing photosensitive molecules
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
US10751398B2 (en) * 2016-10-07 2020-08-25 Loyola University Chicago Inflammasome activators and methods of use to treat tumors
US11285203B2 (en) 2017-06-23 2022-03-29 Verimmune Inc. Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
CN120392995A (zh) 2017-11-06 2025-08-01 美利坚合众国,由健康及人类服务部部长代表 利用预先存在的微生物免疫的癌症治疗
JP2021502822A (ja) 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス
CA3125184A1 (en) 2018-12-27 2020-07-02 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
AU732125B2 (en) * 1996-07-17 2001-04-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious papillomavirus pseudoviral particles
EP1015561B1 (en) * 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
CN1241636A (zh) * 1999-07-05 2000-01-19 第一军医大学珠江医院 抗hpv16e6核酶质粒及其在人乳头瘤病毒与肿瘤治疗中的应用
GB0007231D0 (en) * 2000-03-24 2000-05-17 Chiron Spa Modified rna for gene delivery
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法

Also Published As

Publication number Publication date
JP2007211026A (ja) 2007-08-23
US20050142115A1 (en) 2005-06-30
US20100255027A1 (en) 2010-10-07
US8129144B2 (en) 2012-03-06
US6878541B2 (en) 2005-04-12
US7205126B2 (en) 2007-04-17
JP2003024058A (ja) 2003-01-28
CN1114690C (zh) 2003-07-16
WO2002092796A1 (en) 2002-11-21
JP4472724B2 (ja) 2010-06-02
US20030129728A1 (en) 2003-07-10
CN1333338A (zh) 2002-01-30

Similar Documents

Publication Publication Date Title
JP4472724B2 (ja) パピロマウイルス偽ウイルス及びその調製方法
US7097843B2 (en) Immunogenic peptides from the HPV E7 protein
Kirnbauer et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
Shi et al. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses
US7754430B2 (en) Papilloma virus capsomere vaccine formulations and methods of use
CA2305683C (en) Immunogenic peptides from the hpv e7 protein
AU730733B2 (en) Attenuated microorganism strains expressing HPV proteins
Da Silva et al. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines
Fernando et al. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model
AU9015498A (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
EP1018555A2 (en) Chimeric papilomavirus-like particles
US6020309A (en) Pharmaceuticals based on papillomaviruses
Dupuy et al. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles
JPH08308575A (ja) 組換アデノウイルス
JP2002516291A (ja) パピローマウイルス・ウイルス様粒子による経口免疫感作
US20020197668A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
Oh et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant
US6458362B1 (en) Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes
ZA200200886B (en) Vaccine.
US20040081661A1 (en) Papillomavirus truncated L1 protein and fusion protein constructs
KR100904844B1 (ko) 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
Hu et al. Protective cell-mediated immunity by DNA vaccination against papillomavirus L1 capsid protein in the cottontail rabbit papillomavirus model
Wei et al. Interleukin-12 gene adjuvant increases the immunogenicity of virus-like particles of human papillomavirus type 16 regional variant strain
Onon et al. The use of vaccines in treating cervical cancer: present status and future prospects
US7494658B2 (en) Papilloma virus truncated L1 protein and fusion protein constructs

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070711

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20071109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100506

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees